ArticlesComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Introduction
In the past 20 years, several new drugs have been introduced for the treatment of depression, many of which are structurally related and share similar putative mechanisms of action. As with statins for the prevention of coronary events,1 the extent to which these agents vary in terms of efficacy and acceptability is unclear. Moreover, some of the new drugs are so-called me-too drugs2—ie, chemically similar to existing drugs with expiring patents rather than genuine advances in treatment. Systematic reviews have already highlighted some differences in efficacy between second-generation antidepressants.3, 4, 5, 6, 7, 8, 9
We report an overview of all randomised controlled trials that compared 12 new-generation antidepressants in terms of efficacy and acceptability in the acute-phase treatment of major depression. We used multiple-treatments meta-analysis,10 also known as mixed-treatment comparisons meta-analysis or network meta-analysis, which allows the integration of data from direct (when treatments are compared within a randomised trial) and indirect comparisons (when treatments are compared between trials by combining results on how effective they are compared with a common comparator treatment).11 We aimed to provide a clinically useful summary of the results of the multiple-treatments meta-analysis that can be used to guide treatment decisions.
Section snippets
Study selection and data collection
At the beginning of this project, we drafted a study protocol and subsequently made it freely available to the public on our institutional website before carrying out the final analyses. Furthermore, with the publication of this paper the overall data set will be in the public domain.
For our analysis, we included only randomised controlled trials that compared any of the following 12 new-generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine,
Results
The electronic searches yielded 345 potentially relevant studies, of which 274 potentially eligible articles were analysed. We excluded 172 reports that did not meet eligibility criteria (figure 1). We identified a further 15 unpublished trials eligible for our meta-analysis from pharmaceutical industry websites. Overall, we used 117 trials from 1991 to 2007 for the multiple-treatments meta-analysis.21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
Discussion
Our analysis was based on 117 studies including 25 928 individuals randomly assigned to 12 different new-generation antidepressants. Our findings might help to choose among new-generation antidepressants for acute treatment of major depression. Some antidepressants differed both statistically and clinically. In terms of response, mirtazapine, escitalopram, venlafaxine, and sertraline were more efficacious than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine. In terms of
References (151)
- et al.
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
Biol Psychiatry
(2007) - et al.
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs
Biol Psychiatry
(2008) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine
J Affect Disord
(2006) - et al.
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
J Affect Disord
(1999) - et al.
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine
Clin Ther
(2001) - et al.
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline
Clin Ther
(1999) - et al.
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Eur Neuropsychopharmacol
(2004) - et al.
A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients
Clin Ther
(1998) - et al.
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
J Affect Disord
(2000)